Maze Therapeutics (MAZE) Accumulated Depreciation (2024 - 2025)
Maze Therapeutics recorded quarterly Accumulated Depreciation of $19.2 million in Q4 2025, up 13.9% quarter-over-quarter from $16.9 million in Q4 2024, and up 13.9% year-over-year from $16.9 million in Q4 2024.
Maze Therapeutics' Accumulated Depreciation history runs 2 years deep, the most recent figure standing at $19.2 million for Q4 2025.
- In Q4 2025, Accumulated Depreciation rose 13.9% year-over-year to $19.2 million; the TTM figure through Dec 2025 stood at $19.2 million (up 13.9% YoY), while the FY2025 annual figure was $19.2 million, up 13.9% from the prior year.
- Accumulated Depreciation came in at $19.2 million for Q4 2025 at Maze Therapeutics, up from $16.9 million in the prior quarter.
- In the past five years, Accumulated Depreciation ranged from a high of $19.2 million in Q4 2025 to a low of $16.9 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Maze Therapeutics | 1.37 Bn | 1.37 Bn | 18.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19.21 Mn |
| Dec 31, 2024 | 16.87 Mn |